SLC5A2 and chronic kidney disease: In this study, we hypothesize that our model can recapitulate the clinical trials (DAPA‐CKD and EMPA‐Kidney) that demonstrate renoprotection and attenuation of GFR decline during chronic non‐diabetic CKD treatment with SGLT2 inhibition (Heerspink et al., 2020; The et al., 2023).